Jpmorgan Chase & CO Applied Therapeutics Inc. Transaction History

Jpmorgan Chase & CO

$1.14 Trillion
Q2 2024

A detailed history of Jpmorgan Chase & CO transactions in Applied Therapeutics Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 41,138 shares of APLT stock, worth $394,924. This represents 0.0% of its overall portfolio holdings.

Number of Shares

41,138

Previous 178,924 77.01%

Holding current value

$394,924

Previous $1.22 Million 84.21%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 12, 2024	SELL	$4.04 - $6.37 $556,655 - $877,696	-137,786 Reduced 77.01%	41,138 $192,000
Q1 2024 May 10, 2024	BUY	$2.25 - $7.4 $296,979 - $976,733	131,991 Added 281.23%	178,924 $1.22 Million
Q4 2023 Feb 12, 2024	BUY	$1.84 - $3.35 $85,642 - $155,925	46,545 Added 11996.13%	46,933 $157,000
Q3 2023 Nov 14, 2023	SELL	$1.26 - $2.77 $33,660 - $74,000	-26,715 Reduced 98.57%	388 $0
Q2 2023 Aug 11, 2023	SELL	$0.77 - $1.8 $37,455 - $87,557	-48,643 Reduced 64.22%	27,103 $34,000
Q1 2023 May 11, 2023	BUY	$0.75 - $1.21 $56,518 - $91,183	75,358 Added 19422.16%	75,746 $61,000
Q4 2022 Feb 13, 2023	SELL	$0.54 - $1.12 $888 - $1,843	-1,646 Reduced 80.92%	388 $0
Q3 2022 Nov 14, 2022	BUY	$0.86 - $1.55 $698 - $1,258	812 Added 66.45%	2,034 $2,000
Q2 2022 Aug 11, 2022	SELL	$0.76 - $2.64 $7,849 - $27,265	-10,328 Reduced 89.42%	1,222 $1,000
Q1 2022 May 11, 2022	BUY	$1.48 - $6.22 $3,392 - $14,256	2,292 Added 24.76%	11,550 $25,000
Q4 2021 Feb 10, 2022	BUY	$8.77 - $18.29 $4,270 - $8,907	487 Added 5.55%	9,258 $83,000
Q3 2021 Nov 12, 2021	BUY	$13.54 - $22.06 $118,759 - $193,488	8,771 New	8,771 $146,000

Others Institutions Holding APLT

# of Institutions

101

Shares Held

103M

Call Options Held

777K

Put Options Held

80.8K

View Full List

About Applied Therapeutics Inc.

Ticker APLT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 48,020,700
Market Cap $461M
Description
Applied Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel products to target cardiovascular disease, galactosemia, and diabetic complications. Its lead product candidate is AT-007 that has completed phase 1/2 for the treatment of galactosemia in healthy volunteers and adults, as well as is in pediatric clinical study...

More about APLT

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

News

Stay updated on Jpmorgan Chase & CO with notifications on news.

Account

Jpmorgan Chase & CO Applied Therapeutics Inc. Transaction History